Breaking News

ASLAN Pharma Selects PharmaNet/i3 as Strategic Partner

Will support development of oncology portfolio in Asia

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

ASLAN Pharmaceuticals has selected PharmaNet/i3 as a strategic partner to support the development of its oncology portfolio in Asia, and to conduct Phase I and Phase II trials for two of ASLAN’s compounds.   Dr. Alan Barge, ASLAN’s chief medical officer, said, “We chose to work with PharmaNet/i3 because of the commitment and passion shown by their team and the creative thinking they brought to our oncology development strategy. ASLAN is keen to build a strong strategic relationship with PharmaNe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters